Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the...
For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.